Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver diseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Peio Aristu-Zabalza et al.|Journal of Hepatology|2020Cited by 163
The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for CancerAlbert Gibert‐Ramos, Anabel Fernández‐Iglesias, David Sanfeliu-Redondo et al.|Cancers|2021Cited by 39
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as NutraceuticalZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Paloma Morata et al.|Nutrients|2020Cited by 26
A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver DiseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Estefanía de Gregorio et al.|Nutrients|2019Cited by 22
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal HypertensionChangpeng Zhu, Wei‐Fen Xie, Shuqing Liu et al.|Gastroenterology|2024Cited by 12